Onivyde, also known by its generic name irinotecan hydrochloride liposome, is a chemotherapy drug used to treat pancreatic cancer [1]. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [2]. This means Onivyde works by interfering with the DNA of cancer cells, preventing them from growing and dividing [3].
How is Onivyde Administered?
Onivyde is given intravenously, meaning it is administered directly into a vein by a healthcare professional [4]. The infusion is typically given over a period of 90 minutes [1]. The specific dosage and frequency of administration depend on the patient's individual treatment plan and response to the therapy [4].
What Cancers Does Onivyde Treat?
Onivyde is FDA-approved for the treatment of metastatic adenocarcinoma of the pancreas [1]. It is generally used in combination with other chemotherapy drugs, such as fluorouracil and leucovorin, as part of a treatment regimen [2]. This combination therapy aims to improve outcomes for patients with this specific type of advanced pancreatic cancer.
What Are the Potential Side Effects of Onivyde?
Like other chemotherapy drugs, Onivyde can cause a range of side effects. Common side effects may include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis (mouth sores) [5]. More serious side effects can occur, and patients should discuss any concerns with their doctor. Diarrhea is a particularly important side effect to monitor, as severe diarrhea can lead to dehydration and electrolyte imbalances [5].
How Does Onivyde Work Differently Than Standard Irinotecan?
The liposomal formulation of Onivyde is designed to alter the way irinotecan is delivered in the body. Liposomes are tiny fat bubbles that encapsulate the drug, which can affect its distribution, metabolism, and duration of action. This can potentially lead to a more sustained release of the drug at the tumor site and potentially different side effect profiles compared to non-liposomal irinotecan [2].
What Is the Role of Patents for Onivyde?
Drug patents are crucial for Onivyde, as they protect the manufacturer's exclusive rights to sell the drug for a certain period. This exclusivity allows companies to recoup their research and development costs. Information on the patent status and potential patent expirations for Onivyde can be found on specialized resources like DrugPatentWatch.com [6].
Who Manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1].
Sources
1. https://www.drugs.com/onivyde.html
2. https://www.cancer.gov/about-cancer/treatment/drugs/irinotecan
3. https://www.cancer.gov/publications/dictionaries/cancer-drug-term/idinotecan
4. https://www.webmd.com/drugs/2/200836/onivyde/details
5. https://www.rxlist.com/onivyde-side-effects-drug-center.htm
6. https://drugpatentwatch.com/